Trial | NCT04479852  Report issue

Title

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    SP-624 ...

  • Study Participants

    319
This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Study Started
Sep 30
2020
Primary Completion
Jun 27
2022
Study Completion
Jun 27
2022
Last Update
Jun 13
2023

Drug SP-624

Oral capsule

Drug Placebo

Oral capsule

SP-624 Experimental

Daily oral capsule, 20 mg/day

Placebo Placebo Comparator

Daily oral capsule

Criteria 

Inclusion Criteria:

Willing and able to provide written informed consent to participate in the study
Males and females, aged 18 to 65 years
In generally good physical health
Body mass index (BMI) must be between 18 and 40 kg/m2
Females of reproductive potential and males with partners of reproductive potential must agree to remain abstinent or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of study drug
Subjects must meet criteria for moderate to severe Major Depressive Disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
Willing and able to comply with the study design schedule and other requirements

Exclusion Criteria:

Female who is pregnant, breastfeeding, or less than six months postpartum at Screening
History or presence of any clinically significant medical condition, disease, or surgical history that could jeopardize the safety of the subject or validity of the study data, or interfere with the absorption, distribution, metabolism, or excretion of the study drug
Failure to discontinue all psychoactive medications or psychoactive supplements including antidepressants and mood stabilizers, within a time period prior to Baseline corresponding to at least five half-lives of the medication in question
Presence of a clinically significant abnormality on physical examination or electrocardiogram (ECG), including a corrected QT interval using Fridericia's formula (QTcF) >450 msec for males and >470 msec for females
Presence of uncontrolled hypertension, defined as consistent systolic blood pressure (SBP) >160 mmHg or consistent diastolic blood pressure (DBP) >95 mmHg despite present therapy
Screening laboratory value(s) outside the laboratory reference range that are considered to be clinically significant by the Investigator (clinical chemistry, hematology, coagulation, and urinalysis)
Screening liver function tests (ALT, AST, Alkaline phosphatase) > 2x the upper limit of normal
Subjects who, in the opinion of the Investigator, are not suitable candidates for the study
No Results Posted